Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Perspective Therapeutics, with eight buy ratings and one hold among nine analysts. The average 12-month price target is $11.56, versus the stock’s recent price of $3.22.
• Perspective Therapeutics reported a quarterly loss of $0.22 per share, beating the consensus estimate of a $0.25 loss, while revenue totaled $0.08 million. Analysts expect a full-year loss of approximately $1.05 per share.
• Institutional investors own 54.66% of the company, with several firms initiating or increasing positions. The company is developing precision-targeted alpha therapies, including clinical-stage programs for neuroendocrine tumors and metastatic melanoma.

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) have earned an average rating of "Moderate Buy" from the nine brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $11.5556.

A number of brokerages recently weighed in on CATX. Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. BTIG Research reissued a "buy" rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Bank of America cut their price target on Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday. Finally, Piper Sandler reduced their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating for the company in a research report on Tuesday, August 11th.

Perspective Therapeutics Trading Up 0.6%

Perspective Therapeutics stock opened at $3.22 on Tuesday. Perspective Therapeutics has a twelve month low of $1.96 and a twelve month high of $6.16. The company has a 50 day moving average of $3.09 and a 200-day moving average of $3.95.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.09 million. As a group, analysts anticipate that Perspective Therapeutics will post -1.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors have recently bought and sold shares of CATX. Portland Investment Counsel Inc. acquired a new position in Perspective Therapeutics during the 2nd quarter worth approximately $852,000. Bank of New York Mellon Corp bought a new position in shares of Perspective Therapeutics during the 2nd quarter worth approximately $1,015,000. Taylor & Morgan Wealth Management LLC grew its stake in shares of Perspective Therapeutics by 127.6% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company's stock worth $225,000 after acquiring an additional 37,000 shares in the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Perspective Therapeutics in the first quarter valued at approximately $1,581,000. Finally, Avidity Partners Management LP raised its holdings in shares of Perspective Therapeutics by 88.4% in the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company's stock valued at $25,228,000 after purchasing an additional 2,839,266 shares during the last quarter. Institutional investors own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source